Soluble PD-L1 as an early marker of progressive disease on nivolumab | Journal for ImmunoTherapy of Cancer

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

PDF +
Supplementary
Material

Immunotherapy biomarkers

Original research

Soluble PD-L1 as an early marker of progressive disease on nivolumab

Online download statistics by month:

Online download statistics by month: February 2022 to March 2024

	Abstract	Full	Pdf
Feb 2022	1556	1600	416
Mar 2022	378	408	196
Apr 2022	214	230	113
May 2022	181	184	73
Jun 2022	201	212	73
Jul 2022	232	242	65
Aug 2022	243	246	67
Sep 2022	244	252	131
Oct 2022	263	276	77
Nov 2022	250	251	73
Dec 2022	203	208	35
Jan 2023	160	160	38
Feb 2023	179	180	61
Mar 2023	120	123	55
Apr 2023	118	121	43
May 2023	138	139	50
Jun 2023	121	123	35
Jul 2023	113	113	41
Aug 2023	81	81	20
Sep 2023	94	94	14
Oct 2023	90	91	22
Nov 2023	85	86	25
Dec 2023	88	89	28
Jan 2024	78	78	38
Feb 2024	87	89	25
Mar 2024	86	86	58
Total	5603	5762	1872